Trial Profile

Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-Cell Lymphoma, Followed by Randomized Maintenance With Rituximab

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Carboplatin; Carmustine; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Ifosfamide; Melphalan
Indications Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms CORAL

Most Recent Events

30 Jan 2014 Accural to date is 100% as per United Kingdom Clinical Research Network record.
07 Jun 2011 Final analysis results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
03 Jul 2010 Additional lead trial centre and investigator identified as reported by United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com